Contact this trialFirst, we need to learn more about you.
Anti-metabolites
Pacritinib + Azacitidine for Leukemia
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests a drug combo to treat Chronic Myelomonocytic Leukemia (CMML). Patients must have not previously received a JAK inhibitor. Initial dose is 200mg twice daily, with possible escalation to 100mg if needed. 6-12 patients will be enrolled in phase 1, 12 in phase 2. Interim analysis for futility.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.